Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for clues to CLL drug resistance in new study

NCT ID NCT07099443

Knowledge-focused Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This study aims to understand why some people with chronic lymphocytic leukemia (CLL) respond well to a new class of drugs called BTK degraders, while others do not. Researchers will collect blood, bone marrow, or lymph node samples from 60 patients over 9 years and follow them for 5 years. The goal is to identify resistance mechanisms using advanced lab techniques, which may help improve future treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Sep 2039

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Double refractory CLL patients

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with CLL candidates ou exposed to BTKd * Patient who has provided informed consent to participate in the study. * Patient covered by a social security health insurance plan Exclusion Criteria: * Minor patients. * Adults under guardianship. * Protected persons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BTK degraders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BTK degraders Chronic lymphocytic leukemia Refractory chronic lymphocytic leukemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Régional Universitaire de Nancy

    NOT_YET_RECRUITING

    Nancy, France

  • CHD Vendée

    RECRUITING

    La Roche-sur-Yon, France

  • CHU de Angers

    NOT_YET_RECRUITING

    Angers, France

  • CHU de Bordeaux

    NOT_YET_RECRUITING

    Bordeaux, France

  • CHU de Clermont-Ferrand

    NOT_YET_RECRUITING

    Clermont-Ferrand, France

  • CHU de Montpellier

    NOT_YET_RECRUITING

    Montpellier, France

  • CHU de Poitiers

    NOT_YET_RECRUITING

    Poitiers, France

  • Centre Henri-Becquerel de Rouen

    NOT_YET_RECRUITING

    Rouen, France

  • Centre Léon Bernard

    NOT_YET_RECRUITING

    Lyon, France

  • Hôpital Avicenne (AP-HP)

    NOT_YET_RECRUITING

    Paris, France

  • Hôpital Universitaire Pitié Salpêtrière de Paris

    NOT_YET_RECRUITING

    Paris, France

  • Institut Bergonié

    NOT_YET_RECRUITING

    Bordeaux, France

  • Institut Paoli-Calmettes (Marseille)

    NOT_YET_RECRUITING

    Marseille, France

  • University Hospital

    RECRUITING

    Nantes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.